Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs
- 657 Downloads
The intestinal mucosa and liver have long been considered as the main sites of drug metabolism, and the contribution of gut microbiota to drug metabolism has been under-estimated. However, it is now generally accepted that the gut microbiota plays an important role in drug metabolism prior to drug absorption or during enterohepatic circulation via various microbial enzymatic reactions in the intestine. Moreover, some drugs are metabolized by gut microbiota to specific metabolite(s) that cannot be formed in the liver. More importantly, the metabolism of drugs by gut microbiota prior to absorption can alter the systemic bioavailability of certain drugs. Therefore, understanding drug metabolism by gut microbiota is critical for explaining changes in the pharmacokinetics of drugs, which may cause significant alterations in drug-induced pharmacodynamics and toxicities. In this review, we describe recent progress with regard to the role of metabolism by gut microbiota in some drug-induced alterations of either pharmacological or toxicological effects to emphasize the clinical importance of gut microbiota for safe and effective use of drugs.
KeywordsGut microbiota Drug metabolism Pharmacokinetics Pharmacodynamics Toxicity
This work was supported by grants from National Research Foundation of Korea (NRF-2017R1D1A3B04033313) and from Yeungnam University (214-A-345-027).
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- Chen LZ, Sabo JP, Philip E, Rowland L, Mao Y, Latli B, Ramsden D, Mandarino DA, Sane RS (2015) Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59:25–37CrossRefPubMedGoogle Scholar
- Gorbach SL (1996) Microbiology of the gastrointestinal tract. In: Baron S (ed) Medical microbiology, 4th edn. University of Texas Medical Branch, GalvestonGoogle Scholar
- Nakayama H, Kinouchi T, Kataoka K, Akimoto S, Matsuda Y, Ohnishi Y (1997) Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 7:35–43CrossRefPubMedGoogle Scholar
- Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi K, Watabe T, Ogura Y (1997) Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 25:270–273Google Scholar
- Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L, Rossmann P, Hrncir T, Kverka M, Zakostelska Z, Klimesova K, Pribylova J, Bartova J, Sanchez D, Fundova P, Borovska D, Srutkova D, Zidek Z, Srutkova D, Schwarzer M, Drastich P, Funda DP (2011) The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 8:110–120CrossRefPubMedPubMedCentralGoogle Scholar
- Zhong ZY, Sun BB, Shu N, Xie QS, Tang XG, Ling ZL, Wang F, Zhao KJ, Xu P, Zhang M, Li Y, Chen Y, Liu L, Xia LZ, Liu XD (2016) Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal beta-glucuronidase activity. Acta Pharmacol Sin 37:1002–1012CrossRefPubMedPubMedCentralGoogle Scholar